Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT06262776
NA

Safety and Immunogenicity of Recombinant Zoster Vaccine for Transplant Recipients

Sponsor: Central Adelaide Local Health Network Incorporated

View on ClinicalTrials.gov

Summary

The goal of this clinical trial is to compare responses to Varicella Zoster vaccination between transplant patients on different medication regimens, and their healthy co-habitants. The main questions it aims to answer are: 1. Are there differences in vaccination immunological responses in transplant patients on different immunosuppression regimens? 2. Are there differences in vaccination immunological responses between transplant patients and their healthy co-habitants? Participants will all receive a 2-dose course of SHINGRIX recombinant Zoster vaccination, and have immunological responses measured and compared at 5 timepoints between 1 week to 1 year post-vaccination.

Official title: Safety and Immunogenicity of Recombinant Zoster Vaccine for Transplant Recipients (SIR ZOSTER)

Key Details

Gender

All

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

160

Start Date

2024-03-20

Completion Date

2027-12

Last Updated

2026-04-09

Healthy Volunteers

No

Interventions

BIOLOGICAL

Recombinant zoster vaccine adjuvanted (SHINGRIX)

2 doses of 0.5mL recombinant zoster vaccine adjuvanted intramuscular injection at week 0 and week 8.

Locations (1)

Royal Adelaide Hospital

Adelaide, South Australia, Australia